These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28135086)

  • 1. Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket.
    Sundriyal S; Moniot S; Mahmud Z; Yao S; Di Fruscia P; Reynolds CR; Dexter DT; Sternberg MJ; Lam EW; Steegborn C; Fuchter MJ
    J Med Chem; 2017 Mar; 60(5):1928-1945. PubMed ID: 28135086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD
    Mellini P; Itoh Y; Elboray EE; Tsumoto H; Li Y; Suzuki M; Takahashi Y; Tojo T; Kurohara T; Miyake Y; Miura Y; Kitao Y; Kotoku M; Iida T; Suzuki T
    J Med Chem; 2019 Jun; 62(12):5844-5862. PubMed ID: 31144814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site.
    Rumpf T; Schiedel M; Karaman B; Roessler C; North BJ; Lehotzky A; Oláh J; Ladwein KI; Schmidtkunz K; Gajer M; Pannek M; Steegborn C; Sinclair DA; Gerhardt S; Ovádi J; Schutkowski M; Sippl W; Einsle O; Jung M
    Nat Commun; 2015 Feb; 6():6263. PubMed ID: 25672491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
    Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
    Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.
    Cui H; Kamal Z; Ai T; Xu Y; More SS; Wilson DJ; Chen L
    J Med Chem; 2014 Oct; 57(20):8340-57. PubMed ID: 25275824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study.
    Schiedel M; Rumpf T; Karaman B; Lehotzky A; Oláh J; Gerhardt S; Ovádi J; Sippl W; Einsle O; Jung M
    J Med Chem; 2016 Feb; 59(4):1599-612. PubMed ID: 26696402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug repurposing for ligand-induced rearrangement of Sirt2 active site-based inhibitors via molecular modeling and quantum mechanics calculations.
    Bharadwaj S; Dubey A; Kamboj NK; Sahoo AK; Kang SG; Yadava U
    Sci Rep; 2021 May; 11(1):10169. PubMed ID: 33986372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-(Methyl(phenyl)amino)-N-(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition.
    Kaya SG; Eren G; Massarotti A; Bakar-Ates F; Ozkan E; Gozelle M; Ozkan Y
    Drug Dev Res; 2024 Jun; 85(4):e22224. PubMed ID: 38867474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of inhibitor binding site in human sirtuin 2 using molecular docking and dynamics simulations.
    Sakkiah S; Arooj M; Kumar MR; Eom SH; Lee KW
    PLoS One; 2013; 8(1):e51429. PubMed ID: 23382805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors.
    Scarano N; Abbotto E; Musumeci F; Salis A; Brullo C; Fossa P; Schenone S; Bruzzone S; Cichero E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
    Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
    Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.
    Roshdy E; Mustafa M; Shaltout AE; Radwan MO; Ibrahim MAA; Soliman ME; Fujita M; Otsuka M; Ali TFS
    Eur J Med Chem; 2021 Nov; 224():113709. PubMed ID: 34303869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
    Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
    Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the Slow Off-Kinetics of Sirtuin-Rearranging Ligands (SirReals) by Means of Label-Free Electrically Switchable Nanolever Technology.
    Schiedel M; Daub H; Itzen A; Jung M
    Chembiochem; 2020 Apr; 21(8):1161-1166. PubMed ID: 31692222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells.
    Seifert T; Malo M; Kokkola T; Engen K; Fridén-Saxin M; Wallén EA; Lahtela-Kakkonen M; Jarho EM; Luthman K
    J Med Chem; 2014 Dec; 57(23):9870-88. PubMed ID: 25383691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
    Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
    Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
    Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
    Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening approach by a combination of computational and in vitro experiments: identification of fluvastatin sodium as a potential SIRT2 inhibitor.
    Yang J; Wang H; Liu J; Ma E; Jin X; Li Y; Ma C
    J Mol Model; 2024 May; 30(6):188. PubMed ID: 38801625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opening the Selectivity Pocket in the Human Lysine Deacetylase Sirtuin2 - New Opportunities, New Questions.
    Robaa D; Monaldi D; Wössner N; Kudo N; Rumpf T; Schiedel M; Yoshida M; Jung M
    Chem Rec; 2018 Dec; 18(12):1701-1707. PubMed ID: 29931800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
    Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
    ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.